Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

分组1 - Prothena reported a quarterly loss of $1.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.92, and an improvement from a loss of $1.34 per share a year ago, indicating an earnings surprise of -21.74% [1] - The company generated revenues of $2.83 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 86.72%, compared to revenues of $0.05 million in the same quarter last year [2] - Prothena's shares have declined approximately 47.4% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] 分组2 - The earnings outlook for Prothena is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.94 on revenues of $21.05 million, and for the current fiscal year at -$3.60 on revenues of $80.55 million [7] - The Medical - Biomedical and Genetics industry, to which Prothena belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]